297 related articles for article (PubMed ID: 10953162)
1. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.
Liu XH; Kirschenbaum A; Yao S; Lee R; Holland JF; Levine AC
J Urol; 2000 Sep; 164(3 Pt 1):820-5. PubMed ID: 10953162
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.
Liu XH; Kirschenbaum A; Yao S; Stearns ME; Holland JF; Claffey K; Levine AC
Clin Exp Metastasis; 1999; 17(8):687-94. PubMed ID: 10919714
[TBL] [Abstract][Full Text] [Related]
3. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.
Liu XH; Yao S; Kirschenbaum A; Levine AC
Cancer Res; 1998 Oct; 58(19):4245-9. PubMed ID: 9766645
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M
Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line.
Liu XH; Kirschenbaum A; Lu M; Yao S; Dosoretz A; Holland JF; Levine AC
J Biol Chem; 2002 Dec; 277(51):50081-6. PubMed ID: 12401798
[TBL] [Abstract][Full Text] [Related]
6. NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms.
Zhong H; Willard M; Simons J
Int J Cancer; 2004 Nov; 112(4):585-95. PubMed ID: 15382039
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 promotes prostate cancer progression.
Fujita H; Koshida K; Keller ET; Takahashi Y; Yoshimito T; Namiki M; Mizokami A
Prostate; 2002 Nov; 53(3):232-40. PubMed ID: 12386924
[TBL] [Abstract][Full Text] [Related]
8. Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer.
Connolly EM; Harmey JH; O'Grady T; Foley D; Roche-Nagle G; Kay E; Bouchier-Hayes DJ
Br J Cancer; 2002 Jul; 87(2):231-7. PubMed ID: 12107848
[TBL] [Abstract][Full Text] [Related]
9. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.
Wen B; Deutsch E; Eschwege P; De Crevoisier R; Nasr E; Eschwege F; Bourhis J
J Urol; 2003 Nov; 170(5):2036-9. PubMed ID: 14532848
[TBL] [Abstract][Full Text] [Related]
11. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer.
Chu J; Lloyd FL; Trifan OC; Knapp B; Rizzo MT
Mol Cancer Ther; 2003 Jan; 2(1):1-7. PubMed ID: 12533667
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Raut CP; Nawrocki S; Lashinger LM; Davis DW; Khanbolooki S; Xiong H; Ellis LM; McConkey DJ
Cancer Biol Ther; 2004 Dec; 3(12):1217-24. PubMed ID: 15477758
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
Gately S; Kerbel R
Prog Exp Tumor Res; 2003; 37():179-92. PubMed ID: 12795055
[TBL] [Abstract][Full Text] [Related]
14. Re: Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme.
Gallo O
J Natl Cancer Inst; 2000 Feb; 92(4):346-7. PubMed ID: 10675387
[No Abstract] [Full Text] [Related]
15. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells.
Munkarah AR; Genhai Z; Morris R; Baker VV; Deppe G; Diamond MP; Saed GM
Gynecol Oncol; 2003 Mar; 88(3):429-33. PubMed ID: 12648598
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
17. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis.
Minter HA; Eveson JW; Huntley S; Elder DJ; Hague A
Clin Cancer Res; 2003 May; 9(5):1885-97. PubMed ID: 12738747
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
Dandekar DS; Lokeshwar BL
Clin Cancer Res; 2004 Dec; 10(23):8037-47. PubMed ID: 15585639
[TBL] [Abstract][Full Text] [Related]
19. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2.
Hernández GL; Volpert OV; Iñiguez MA; Lorenzo E; Martínez-Martínez S; Grau R; Fresno M; Redondo JM
J Exp Med; 2001 Mar; 193(5):607-20. PubMed ID: 11238591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
